By VETTAPHARMA reporter: The U.S. Food and Drug Administration (FDA) has approved the combination of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The approval marks the first all-oral, fixed-duration combination regimen authorized for this population and is supported by results from the Phase 3 AMPLIFY trial. The regimen provides another option offering the potential for time off treatment, representing a meaningful advance in long-term disease management.
The FDA approval is based on findings from the global Phase 3 AMPLIFY trial, which evaluated VENCLEXTA in combination with acalabrutinib versus investigator’s choice of chemoimmunotherapy in previously untreated patients.
The study demonstrated a 35% reduction in the risk of disease progression or death compared with chemoimmunotherapy (hazard ratio 0.65; 95% confidence interval: 0.49–0.87; p=0.0038). At the time of analysis, median progression-free survival (PFS) was not reached in the VENCLEXTA plus acalabrutinib arm compared with 47.6 months in the chemoimmunotherapy arm.
Clinical Context
The Phase 3 AMPLIFY trial compared the fixed-duration VENCLEXTA plus acalabrutinib regimen against standard chemoimmunotherapy regimens selected by investigators. The statistically significant improvement in progression-free survival supports the combination’s role as a frontline, chemotherapy-free option for adult patients with CLL.
With median PFS not reached in the combination arm and a hazard ratio of 0.65, the results indicate durable disease control relative to chemoimmunotherapy. The defined treatment duration approach also provides patients with the potential opportunity to complete therapy and discontinue treatment, aligning with evolving strategies focused on time-limited targeted therapy. AbbVie stated that this approval expands frontline treatment options and reflects continued advancement in targeted approaches for CLL management.
